Core Insights - BetterLife Pharma Inc. has appointed Doug Drysdale as Corporate Advisor to advance the development of BETR-001 for non-psychiatric indications, specifically targeting cluster headaches and migraines [1][4] Company Overview - BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic derivative of LSD, for various neurological disorders [5] - BETR-001 is currently in preclinical and IND-enabling studies and is unique in being unregulated, allowing for self-administration [5] - The company holds a synthesis patent for BETR-001, which eliminates regulatory hurdles, and a pending patent covering treatment methods for neurological disorders until around 2042 [5] Leadership and Experience - Doug Drysdale has a proven track record in the biotech industry, having led Cybin from molecule inception to Phase 3 trials in three years [2] - He previously served as Founding CEO of Alvogen, growing the company to $500 million in revenues across 35 countries in 5.5 years [3] - Drysdale has also held leadership roles in other pharmaceutical companies, significantly increasing their enterprise values and revenues [3] Product Development - BETR-001 has shown promise in reducing cluster headache frequency in a small clinical study, indicating its potential effectiveness [4] - The company is also exploring strategic alternatives for the development of another drug candidate aimed at treating viral infections [6]

Core Insights - NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year seizure-free, significantly improving her quality of life [1][2]. Company Overview - NeuroOne is focused on developing and commercializing minimally invasive and high-definition solutions for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The OneRF® Ablation System is the first FDA 510(k)-cleared device that utilizes the same sEEG electrode for both diagnostic and therapeutic applications, allowing for monitoring, mapping, and ablation at the bedside [3]. Product Performance - The OneRF® Ablation System has demonstrated seizure reduction or freedom for most patients who have undergone the procedure [3]. - Clara's experience highlights the effectiveness of the OneRF® platform, as she transitioned from experiencing multiple seizures daily to being completely seizure-free [4]. Future Developments - The company plans to leverage the OneRF® technology for additional applications, including the OneRF® Trigeminal Nerve Ablation System aimed at treating facial pain, with a 510(k) submission filed to the FDA in April 2025 [4].

Core Insights - NeuroOne Medical Technologies Corporation has appointed Dr. Parag G. Patil as Chief Medical Advisor to enhance its clinical development strategy and growth with new technologies [1][4] Company Overview - NeuroOne is focused on developing and commercializing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for patients with neurological disorders such as epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to improve patient outcomes and reduce procedural costs while exploring applications in other areas like depression and artificial intelligence [5] Leadership and Expertise - Dr. Parag G. Patil brings over 20 years of experience in clinical care and medical innovation, having served in various academic and leadership roles [2][4] - His background includes a B.S. in electrical engineering from MIT, a Marshall Scholarship for studies at Oxford, and advanced medical training at Johns Hopkins and Duke University [3] Strategic Goals - In his new role, Dr. Patil will assist with NeuroOne's clinical strategy, product development, and partnerships with professional societies, leveraging his extensive experience with the company's technology [4] - The company aims to transform the diagnosis and treatment of neurological disorders, potentially reducing the number of surgeries and hospitalizations while improving efficacy [4]

Core Insights - Addex Therapeutics has entered into an option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property related to mGlu5 inhibitors aimed at brain injury recovery [1][2] - The collaboration will focus on the preclinical validation of Addex's lead drug candidate, dipraglurant, which is an mGlu5 negative allosteric modulator [2][3] - The mGlu5 receptor is believed to play a significant role in brain plasticity and functional recovery following brain injuries such as strokes [4] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in novel small molecule allosteric modulators for neurological disorders [5] - The company's lead candidate, dipraglurant, is being evaluated for its potential in treating brain injury recovery, including post-stroke and traumatic brain injury [5] - Addex also has partnerships and programs targeting other neurological conditions, including a GABAB PAM program for chronic cough and a 20% equity interest in Neurosterix LLC [5]